Variable | Proportion affected among patients with diabetes, n (%) (N=32 201) |
Age, mean (SD) | 63.4 (13.3) |
18–50 | 5520 (17.1) |
51–60 | 7595 (23.6) |
61–70 | 8330 (23.9) |
71–80 | 7836 (24.3) |
>80 | 2920 (9.1) |
Women | 14 669 (45.6) |
Men | 17 532 (54.4) |
General practice | 21 310 (66.2) |
Specialized diabetes practices | 10 891 (33.8) |
Codiagnoses documented prior to NAFLD diagnosis or end of follow-up | |
Diabetic renal complications | 6177 (19.2) |
Diabetic neuropathy | 3582 (11.1) |
Lipid metabolism disorders | 16 047 (49.8) |
Hypertension | 24 749 (76.9) |
Chronic coronary heart disease | 7965 (24.7) |
History of myocardial infarction | 2681 (8.3) |
History of stroke/TIA | 2707 (8.4) |
Peripheral vascular disease | 4484 (13.9) |
HbA1c, mean (SD) | 7.2 (1.4) |
<6.5 | 10 682 (33.2) |
6.5–7.4 | 11 168 (34.7) |
7.5–8.4 | 5642 (17.5) |
8.5–9.4 | 2481 (7.7) |
≥9.5 | 2228 (6.9) |
BMI, mean (SD) | 30.9 (6.0) |
<25.0 | 4906 (15.2) |
25.0–29.9 | 10 416 (32.4) |
30.0–34.9 | 9283 (28.8) |
≥35 | 7596 (23.6) |
Antihyperglycemic drugs prescribed prior to NAFLD diagnosis or end of follow-up | |
Metformin | 25 459 (79.1) |
Sulfonylureas | 3370 (10.5) |
DPP-4 inhibitors | 12 620 (39.2) |
SGLT2 inhibitors | 6163 (19.1) |
GLP-1 receptor agonists | 2647 (8.2) |
Insulin | 13 366 (41.5) |
Other drugs | 1195 (3.7) |
Proportions of patients given in %, unless otherwise indicated.
BMI, body mass index; DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; HbA1c, hemoglobin A1c; NAFLD, non-alcoholic fatty liver disease; SGLT2, sodium-glucose cotransporter-2; TIA, transient ischemic attack.